Advanced in Squamous Cell Lung Carcinoma

Xingsheng S. Hu

Beijing Key Laboratory Of Clinical Study On Anticancer Molecular Targeted Drugs, Chinese Academy Of Medical Sciences & Peking Union Medical College, 
Beijing, CN 
Advanced in Squamous Cell Lung Carcinoma
Beijing Key Laboratory Of Clinical Study On Anticancer Molecular Targeted Drugs, Chinese Academy Of Medical Sciences & Peking Union Medical College, 
Beijing, CN 
OverviewLocationsClinical Research

Overview

Xingsheng Hu practices in Beijing, China. Hu is rated as an Advanced expert by MediFind in the treatment of Squamous Cell Lung Carcinoma. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and EGFR Positive Lung Cancer.

Their clinical research consists of co-authoring 104 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 3 articles in the study of Squamous Cell Lung Carcinoma.

Locations

Beijing Key Laboratory Of Clinical Study On Anticancer Molecular Targeted Drugs, Chinese Academy Of Medical Sciences & Peking Union Medical College, Beijing, China
Other Locations
Changsha, China
P.R. China, Nanchong, 637000, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
A Randomized, Open-label, Active-controlled, Multicenter Phase 3 Study to Investigate the Efficacy and Safety of Roxadustat for Treatment of Anemia in Subjects Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Enrollment Status: Completed
Publish Date: June 06, 2023
Intervention Type: Drug
Study Phase: Phase 3

104 Total Publications

Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.
Journal: Thoracic cancer
Published: June 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hu's expertise for a condition
ConditionClose
    View All 9 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile